You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

List of Excipients in API TAZAROTENE


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing TAZAROTENE

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Allergan Inc TAZORAC tazarotene 0023-8335 ASCORBIC ACID
Allergan Inc TAZORAC tazarotene 0023-8335 BENZYL ALCOHOL
Allergan Inc TAZORAC tazarotene 0023-8335 BUTYLATED HYDROXYANISOLE
Allergan Inc TAZORAC tazarotene 0023-8335 BUTYLATED HYDROXYTOLUENE
Allergan Inc TAZORAC tazarotene 0023-8335 CARBOMER HOMOPOLYMER TYPE B
Allergan Inc TAZORAC tazarotene 0023-8335 EDETATE DISODIUM
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Excipients in ANDA-approved (generic) drugs containing TAZAROTENE

Company Ingredient NDC Excipient
Fougera Pharmaceuticals Inc tazarotene 0168-0454 BENZYL ALCOHOL
Fougera Pharmaceuticals Inc tazarotene 0168-0454 CARBOMER COPOLYMER TYPE B
Fougera Pharmaceuticals Inc tazarotene 0168-0454 CARBOMER HOMOPOLYMER TYPE B
Fougera Pharmaceuticals Inc tazarotene 0168-0454 EDETATE DISODIUM
Fougera Pharmaceuticals Inc tazarotene 0168-0454 MEDIUM-CHAIN TRIGLYCERIDES
Fougera Pharmaceuticals Inc tazarotene 0168-0454 MINERAL OIL
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for TAZAROTENE

Excipient focus: ANHYDROUS CITRIC ACID

Excipient focus: ASCORBIC ACID

Excipient focus: BENZYL ALCOHOL

Excipient focus: BUTYLATED HYDROXYANISOLE

Excipient focus: BUTYLATED HYDROXYTOLUENE

Excipient focus: CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES

Excipient focus: CARBOMER 1342

Excipient focus: CARBOMER COPOLYMER TYPE A

Excipient focus: CARBOMER COPOLYMER TYPE B

Excipient focus: CARBOMER HOMOPOLYMER TYPE A

Excipient focus: CARBOMER HOMOPOLYMER TYPE B

Excipient focus: CETEARETH-12

Excipient focus: DIETHYL SEBACATE

Excipient focus: DIISOPROPYL ADIPATE

Excipient focus: EDETATE DISODIUM

Excipient focus: GLYCERYL CAPRYLOCAPRATE

Excipient focus: GLYCERYL MONO- AND DICAPRYLOCAPRATE

Excipient focus: HEXYLENE GLYCOL

Excipient focus: LIGHT MINERAL OIL

Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES

TAZAROTENE drug variants containing MEDIUM-CHAIN TRIGLYCERIDES

Company Ingredient NDC
Fougera Pharmaceuticals Inc tazarotene 0168-0454
E Fougera & Co a division of Fougera Pharmaceuticals Inc tazarotene 0168-0455
Cosette Pharmaceuticals Inc tazarotene 0713-0670
Cosette Pharmaceuticals Inc tazarotene 0713-0764
Padagis Israel Pharmaceuticals Ltd tazarotene 45802-706
Taro Pharmaceuticals USA Inc tazarotene 51672-1373
>Company >Ingredient >NDC

Subscribe to access the full database, or Get Started Free

Excipient focus: METHYLPARABEN

Excipient focus: MINERAL OIL

Excipient focus: POLOXAMER 407

Excipient focus: POLYETHYLENE GLYCOL 400

Excipient focus: POLYSORBATE 40

Excipient focus: POTASSIUM CITRATE

Excipient focus: POTASSIUM SORBATE

Excipient focus: PROPYLPARABEN

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM THIOSULFATE

Excipient focus: SORBIC ACID

Excipient focus: SORBITAN MONOOLEATE

Excipient focus: SORBITOL

Excipient focus: TROMETHAMINE

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links